Literature DB >> 2578868

Studies on circulating antibody against carcinoembryonic antigen (CEA) and CEA-like antigen in cancer patients.

Y Ura, Y Ochi, M Hamazu, M Ishida, K Nakajima, T Watanabe.   

Abstract

Characteristics of auto-antibodies for carcinoembryonic antigen (CEA) detected in sera from 3 cancer patients (2 colorectal and 1 breast cancer) were examined. The antibodies belonged to polyclonal immunoglobulin G (IgG). The binding of auto-antibodies with the labeled CEA was inhibited by not only the unlabeled CEA but also NCA-2 (feces and meconium). However, no binding with NCA was observed. Among these auto-antibodies the antibody directed against blood group Lewis determinants which are known to be present in many purified CEA preparations was not found. Previously we had suggested that CEA, NCA-2 and NCA may contain immune determinant in common with alpha 1-acid glycoprotein (AG). These auto-antibodies showed significantly enhanced reactivity for the labeled CEA preparation after purification by anti-AG affinity chromatography in spite of no immunological reaction with AG. These results suggest that auto-antibodies are raised against the common antigenic determinants of both CEA and NCA-2 which do not exist in NCA. These antibodies might be directed to common amino acid sequence shared by CEA and NCA-2, though not excluding the carbohydrate moiety. We surveyed about 500,000 cancer patients but could find only 3 patients who showed a difference in the values of CEA by the indirect and direct method. Thus, the existence of this type auto-antibody to CEA in cancer patients is a rare phenomenon.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2578868     DOI: 10.1016/s0304-3835(15)30008-2

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  8 in total

Review 1.  Oncolytic measles virus strains in the treatment of gliomas.

Authors:  Cory Allen; Georgia Paraskevakou; Chunsheng Liu; Ianko D Iankov; Pavlos Msaouel; Paula Zollman; Rae Myers; Kah Whye Peng; Stephen J Russell; Evanthia Galanis
Journal:  Expert Opin Biol Ther       Date:  2008-02       Impact factor: 4.388

Review 2.  Usage of cancer associated autoantibodies in the detection of disease.

Authors:  Steven P Dudas; Madhumita Chatterjee; Michael A Tainsky
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

3.  Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas.

Authors:  Rae Myers; Mary Harvey; Timothy J Kaufmann; Suzanne M Greiner; James W Krempski; Corey Raffel; Steven E Shelton; Diane Soeffker; Paula Zollman; Mark J Federspiel; Michael Blanco; Evanthia Galanis
Journal:  Hum Gene Ther       Date:  2008-07       Impact factor: 5.695

4.  CEA-containing immune complexes in sera of patients with colorectal and breast cancer--analysis of complexed immunoglobulin classes.

Authors:  C Fuchs; F Krapf; P Kern; S Hoferichter; W Jäger; J R Kalden
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

5.  The presence of anti-carcinoembryonic antigen (CEA) antibodies in the sera of patients with gastrointestinal malignancies.

Authors:  M M Konstadoulakis; K N Syrigos; C Albanopoulos; G Mayers; B Golematis
Journal:  J Clin Immunol       Date:  1994-09       Impact factor: 8.317

Review 6.  Carcinoembryonic antigen: function in metastasis by human colorectal carcinoma.

Authors:  J M Jessup; P Thomas
Journal:  Cancer Metastasis Rev       Date:  1989-12       Impact factor: 9.264

Review 7.  Biological therapy: approaches in colorectal cancer. Strategies to enhance carcinoembryonic antigen (CEA) as an immunogenic target.

Authors:  A P Zbar; N R Lemoine; M Wadhwa; H Thomas; D Snary; W A Kmiot
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

Review 8.  Autoimmunity and Gastric Cancer.

Authors:  Nicola Bizzaro; Antonio Antico; Danilo Villalta
Journal:  Int J Mol Sci       Date:  2018-01-26       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.